SCHEMBL1317243

SCHEMBL1317243

Cc1ccc(O)c(C(=O)Nc2cc(-c3ccccc3)ccc2C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 6/20 0.56
GAA P10253 1/20 0.56
MCL1 Q07820 4/20 0.55
HDAC1 Q13547 3/20 0.54
ACMSD Q8TDX5 3/20 0.54
HNF4A P41235 2/20 0.54
DHFR P00374 1/20 0.54
HDAC2 Q92769 1/20 0.53
CSNK2A1 P68400 1/20 0.53
KDM4E B2RXH2 1/20 0.51
APOBEC3A P31941 1/20 0.51
GFER P55789 1/20 0.51
APOBEC3G Q9HC16 1/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
RAB9A P51151 1/20 0.51
HSD17B10 Q99714 1/20 0.51
KCNMA1 Q12791 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316633 0.91 ACLY (0.57) ACLYGAAMCL1HDAC1ACMSD
SCHEMBL1318525 0.91 ACLY (0.67) ACLYMCL1HDAC1ACMSDHNF4A
SCHEMBL13206537 0.87 ACLY (0.59) ACLYMCL1HDAC1ACMSDHNF4A
SCHEMBL12166105 0.86 HDAC1 (0.51) ACLYGAAMCL1HDAC1HDAC2
SCHEMBL2272453 0.85 ACLY (0.63) ACLYGAAMCL1HDAC1ACMSD
SCHEMBL1315920 0.85 ACLY (0.57) ACLYMCL1HDAC1ACMSDHNF4A
SCHEMBL1317888 0.85 HDAC1 (0.49) ACLYGAAHDAC1HDAC2KDM4E
SCHEMBL1315890 0.85 ACLY (0.67) ACLYMCL1HDAC1ACMSDHNF4A
SCHEMBL13206145 0.85 ACLY (0.56) ACLYMCL1HDAC1ACMSDHNF4A
SCHEMBL1316555 0.85 ACLY (0.56) ACLYMCL1HDAC1ACMSDHNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed
WO-2010087430-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF 富山化学工業株式会社 (JP) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 ACLY 295/4885GAA 877/4885MCL1 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.